Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754346 | 0.95 | HSD17B10 (0.34) | HSD17B10EPHX2CASRKDM4E | |
| SCHEMBL25754373 | 0.91 | ALDH1A1 (0.35) | HSD17B10CASRUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL25754383 | 0.84 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL25754359 | 0.83 | ADRB2 (0.32) | — | |
| SCHEMBL25754377 | 0.82 | HSD17B10 (0.37) | HSD17B10CASRUSP2 | |
| SCHEMBL25754366 | 0.77 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL25754242 | 0.73 | USP2 (0.49) | HSD17B10USP2 | |
| SCHEMBL25754230 | 0.73 | USP2 (0.44) | HSD17B10USP2KDM4E | |
| SCHEMBL5933429 | 0.73 | TSHR (0.41) | HSD17B10EPHX2ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL25754384 | 0.72 | SAT1 (0.34) | USP2ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | HSD17B10 2815/4885EPHX2 2419/4885CASR 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.